ABCL-193 Impact of Bridging Therapy (BT) on Lisocabtagene Maraleucel (liso-cel) as Second-Line (2L) or Later (2L+) Treatment of R/R Follicular Lymphoma (FL) in the Phase 2, Open-Label TRANSCEND FL Study
Dahiya S, Hirayama A, Schuster S, Ortega J, Morschhauser F, Garcia-Sancho A, Kuruvilla J, Izutsu K, Barbui A, Borchmann P, Mielke S, Cartron G, Ghesquieres H, Goto H, Varadarajan I, Kamdar M, Isufi I, Farazi T, Kao G, Vedal M, Bhatnagar R, Nishii R, Papuga J, Palomba M. ABCL-193 Impact of Bridging Therapy (BT) on Lisocabtagene Maraleucel (liso-cel) as Second-Line (2L) or Later (2L+) Treatment of R/R Follicular Lymphoma (FL) in the Phase 2, Open-Label TRANSCEND FL Study. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s462-s463. DOI: 10.1016/s2152-2650(24)01497-6.Peer-Reviewed Original ResearchLiso-celDuration of responseFollicular lymphomaBridging therapyBT subgroupR/R follicular lymphomaMedian follow-upHigh-risk populationSlow disease progressionFL diagnosisLisocabtagene maraleucelSecond-lineCR ratePrimary endpointSecondary endpointsInvestigator's discretionSafety profileFollow-upConsenting patientsDisease progressionSafety signalsOutpatient monitoringImprove outcomesResponse rateOutpatient setting